Mo Yueting, He Xiyuan, Cui Hao, Cheng Yifan, Zhou Mingmei, Cui Xiuming, Zhang Ting
Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
School of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, China; Key Laboratory of Sustainable Utilization of Panax Notoginseng Resources of Yunnan Province, State Administration of Traditional Chinese Medicine, Kunming, 650500, China.
J Ethnopharmacol. 2025 Feb 11;341:119306. doi: 10.1016/j.jep.2024.119306. Epub 2025 Jan 4.
Panax notoginseng (Burkill) F.H.Chen(P. notoginseng) has been widely used as an herbal medicine for reducing swelling, relieving pain, promoting blood circulation and stopping bleeding, with notable therapeutic effects on obesity, liver diseases, colitis, Alzheimer's disease, chronic kidney disease and other diseases.
This review highlighted the close link and bidirectional effects between P. notoginseng and gut microbiota, with the ultimate aim of providing new insights into the potential mechanisms of pharmacological effects of P. notoginseng in the treatment of different diseases and PNS transformation.
By means of some reputable databases (PubMed, China National Knowledge Infrastructure (CNKI), Google Scholar, etc.), we screened the published articles related to P. notoginseng from 1998 to 2024, including original research, clinical trials and review on raw materials and chemical constituents of P. notoginseng. Then, we employed the keywords "gut microbiota", "intestinal microbiota", "gut biotransformation" and "intestinal" to exclude the articles that do not in line with our topic. Plant information was obtained from www.worldfloraonline.org using "Panax notoginseng (Burkill) F.H.Chen" as the keyword.
P. notoginseng elevated certain probiotics including Lactobacillus, Bifidobacterium and Akkermansia, while simultaneously reducing pathogenic bacteria such as Prevotellaceae, Enterococcus, Enterobacter and Helicobacter, to fight various diseases. Meanwhile, considering to the low oral bioavailability and degradable properties of Panax notoginseng saponin (PNS), gut microbiota converted it into protopanaxatriol(PPT) and protopanaxadiol(PPD) mainly through deglycosylation reactions to enhance the bioactivity.
Increasing evidences suggest that gut microbiota may play a vital role for P. notoginseng exerting on beneficial effects on the prevention and treatment of metabolic disorders, liver diseases, neurological diseases, chronic kidney diseases, vascular diseases, colitis, and other diseases, as well as for biotransformation of P. notoginseng.
三七(Panax notoginseng (Burkill) F.H.Chen)作为一种草药,已被广泛用于消肿、止痛、促进血液循环和止血,对肥胖症、肝脏疾病、结肠炎、阿尔茨海默病、慢性肾脏病等疾病具有显著的治疗作用。
本综述强调了三七与肠道微生物群之间的紧密联系和双向作用,最终目的是为三七治疗不同疾病的药理作用及三七总皂苷转化的潜在机制提供新的见解。
通过一些知名数据库(PubMed、中国知网(CNKI)、谷歌学术等),我们筛选了1998年至2024年期间与三七相关的已发表文章,包括原始研究、临床试验以及关于三七原材料和化学成分的综述。然后,我们使用关键词“肠道微生物群”“肠道菌群”“肠道生物转化”和“肠道”来排除不符合我们主题的文章。使用关键词“Panax notoginseng (Burkill) F.H.Chen”从www.worldfloraonline.org获取植物信息。
三七可提高某些益生菌的数量,包括乳酸杆菌、双歧杆菌和阿克曼氏菌,同时减少诸如普雷沃氏菌科、肠球菌、肠杆菌和幽门螺杆菌等病原菌,以对抗各种疾病。同时,考虑到三七总皂苷(PNS)口服生物利用度低和可降解的特性,肠道微生物群主要通过去糖基化反应将其转化为原人参三醇(PPT)和原人参二醇(PPD),以增强生物活性。
越来越多的证据表明,肠道微生物群可能在三七对代谢紊乱、肝脏疾病、神经疾病、慢性肾脏疾病、血管疾病、结肠炎等疾病的预防和治疗发挥有益作用以及三七的生物转化过程中起着至关重要的作用。